SCG Cell Therapy And A*STAR Launch Joint Labs To Advance iPSC Technology For Scalable GMP Manufacturing Of Cellular Immunotherapies
Collaboration aims to develop scalable GMP-grade iPSC manufacturing processes and therapeutic candidates to facilitate research leading to translation of novel cellular immunotherapies.
Launch of the joint labs builds on existing license, research collaboration and Memorandum of Understanding between SCG Cell Therapy and A*STAR.
NMDP BioTherapies Introduces Enhanced Cellular Materials for Allogeneic Cell Therapy Development
First of Its Kind Clinical-Grade Leukopak Now Facilitates Easier Regulatory Filing with Access to a DMF and Identification of Additional Characteristics Required to Qualify Cord Blood Units as Starting Material for Manufacture of Cell and Gene Therapies
MINNEAPOLIS– NMDP BioTherapies℠ formerly Be The Match BioTherapies, a leader in cell and gene therapy development support, unveiled substantial upgrades to its cellular starting material offerings, including incorporating a Drug Master File (DMF) with its rapid-delivery, standard GMP leukopak to simplify regulatory filings. The strategic enhancements to its suite are designed to address the evolving needs of the allogeneic cell therapy industry, emphasizing optimized delivery times, customizable options, and expanded capabilities. [Read more…]
Panasonic and Shinobi Therapeutics Partner to Develop Efficient and Cost-Effective iPS Cell Therapy Manufacturing Technology
Panasonic to create a closed-system manufacturing device based on Shinobi’s innovative iPS-T cell platform and cutting-edge research at Kyoto University
Partnership aimed at significantly broadening accessibility of cell therapies to patients on a global scale
SAN FRANCISCO and KYOTO, Japan, April 18, 2024 — Shinobi Therapeutics, a biotechnology company developing a new class of immune evasive iPS cell therapies, today announced a partnership with Panasonic Holdings Corp and Kyoto University’s Center for iPS Cell Research and Application (CiRA). Through this strategic collaboration, the organizations aim to engineer a novel manufacturing platform to produce iPS-T cell therapies more efficiently and at lower cost than is possible with currently available technology. [Read more…]
Polyclonal Antibody Binding To Off-Target Proteins
If you’ve ever run a clean experiment on paper but ended up with messy, confusing results, you’re not alone. One of the most common frustrations researchers face is unexpected bands or signals caused by polyclonal antibody binding to off-target proteins. It’s especially tricky because polyclonal antibodies are widely used for their sensitivity, yet that same strength can quickly turn into a drawback. [Read more…]
- « Previous Page
- 1
- …
- 105
- 106
- 107
- 108
- 109
- …
- 339
- Next Page »